Skip to main content

Advertisement

Table 1 Baseline clinicopathologic characteristics of patients with first-line treatment

From: Right- and left-sided colorectal cancers respond differently to cetuximab

Clinicopathologic characteristic   Cetuximab group Chemotherapy alone group P value d
   All patients RSCC LSCRC P value   All patients RSCC LSCRC P value  
No. of patients   110 33 77   117 61 56 0.001*
Median age at diagnosis      0.420      0.502 0.613
    ≤65 years   90 (81.8) 29 (87.9) 62 (80.5)    93 (79.5) 50 (82.0) 43 (76.8)   
    >65 years   20 (18.2) 4 (12.1) 15 (19.5)    24 (20.5) 11 (18.0) 13 (23.2)   
Sex      0.274      0.085 0.404
    Male   75 (68.2) 20 (60.6) 55 (71.4)    73 (62.4) 43 (70.5) 30 (53.6)   
    Female   35 (31.8) 13 (39.4) 22 (28.6)    44 (37.6) 18 (29.5) 26 (46.4)   
ECOG performance status      0.300      0.367 0.113
    0   49 (44.5) 11 (33.3) 38 (49.4)    49 (41.9) 29 (47.5) 20 (35.7)   
    1   58 (52.7) 21 (63.6) 37 (48.1)    57 (48.7) 26 (42.6) 31 (55.4)   
    ≥2   3 (2.7) 1 (3.0) 2 (2.6)    11 (9.4) 6 (9.8) 5 (8.9)   
Pathology      0.003*      0.116 0.608
    Adenocarcinoma   101 (91.8) 26 (78.8) 75 (97.4)    110 (94.0) 55 (90.2) 55 (98.2)   
    Mucinous & signet-ring cell   9 (8.2) 7 (21.2) 2 (2.6)    7 (6.0) 6 (9.8) 1 (1.8)   
Metastasis      0.674      0.015* 0.893
    Single   67 (60.9) 19 (57.6) 48 (62.3)    70 (59.8) 43 (70.5) 27 (48.2)   
    Multiple   43 (39.1) 14 (42.4) 29 (37.7)    47 (40.2) 18 (29.5) 29 (51.8)   
Metastasis resection   29 (26.4) 6 (18.2) 23 (29.9) 0.244   28 (23.9) 15 (24.6) 13 (23.2) 1.000 0.760
Total cycles of cetuximaba   8 (2–29) 9 (2–29) 8 (2–29) 0.537  
Total cycles of chemotherapya   13 (2–43) 13 (3–38) 13 (2–43) 0.928   13 (2–38) 14 (2–38) 13 (4–38) 0.546 0.344
All three active drugsb   73 (66.4) 24 (72.7) 49 (63.6) 0.388   89 (76.1) 48 (78.7) 41 (73.2) 0.522 0.109
Backbone chemotherapy      0.029*      0.041* 0.003*
    Oxaliplatin-based   37 (33.6) 6 (18.2) 31 (40.3)    63 (53.8) 27 (44.3) 36 (64.3)   
    Irinotecan-based   73 (66.4) 27 (81.8) 46 (59.7)    54 (46.2) 34 (55.7) 20 (35.7)   
Bevacizumab during the disease   44 (40.0) 15 (45.5) 29 (37.7) 0.525   38 (32.5) 24 (39.3) 14 (25.0) 0.116 0.270
Recurrent diseasec   31 (28.2) 6 (18.2) 25 (32.5) 0.230   32 (27.4) 18 (29.5) 14 (25.0) 0.679 1.000
  1. aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses. b Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the course of their disease. c Patients who had metastatic disease after curative-intent primary tumor resection. d Patient characteristics were compared between the cetuximab and chemotherapy groups. ECOG, Eastern Cooperative Oncology Group; RSCC, right-sided colon cancer; LSCRC, left-sided colorectal cancer